Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 4830

Next Previous
X
Search
Drug Profile

MK 4830

Alternative Names: MK-4830

Latest Information Update: 08 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Merck Sharp & Dohme; Presage Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase 0 Head and neck cancer; Soft tissue sarcoma
  • Discontinued Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 16 Oct 2024 Merck Sharp & Dohme completes a phase-II trial in Ovarian cancer (Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in Singapore, Poland, USA, Taiwan, South Korea, Italy, Israel, France, Chile, Canada, Belgium (IV) (NCT05446870; EudraCT2021-005458-27)
  • 17 Jun 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in Australia, China, France, Greece, Japan, South Korea, Poland, Poland, South Africa, Spain (IV)
  • 17 Jun 2024 Discontinued - Phase-I for Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in Australia, China, France, Greece, Japan, South Korea, Poland, Poland, South Africa, Spain (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top